Immuno-combined treatment versus radio-combined treatment in limited-stage small-cell lung cancer.

With a total of 60 LS-SCLC patients receiving immuno-combined treatment therapy, median OS (NR vs 15.4 months, p = 0.091) and median PFS (14.9 vs 12.7 months, p = 0.19) were longer in the cohort of PD-L1 inhibitor-treated patients than PD-1 inhibitor-treated patients, although this difference did not reach statistical significance ( Figure S3 ).

also in 111,027 other papers